Sign up USA
Proactive Investors - Run By Investors For Investors

Ventripoint increases placement to C$3.2mln

VentriPoint Diagnostics shares shot up by a fifth on Wednesday after the company said it is increasing the maximum gross proceeds of its non-brokered private placement to C$3.2mln from C$2mln and will now issue up to 10 million units at 32 cents per unit
Ventripoint increases placement to C$3.2mln
Private placement proceeds upped to C$3.2mln

VentriPoint Diagnostics (CVE:VPT) shares shot up by a fifth on Wednesday after the company said it is increasing the maximum gross proceeds of its non-brokered private placement to C$3.2mln from C$2mln and will now issue up to 10 million units at 32 cents per unit.

Read: VentriPoint arranges C$2mln placement

WATCH: 'We have a shot at a multi-billion dollar company' ...

Each unit consists of one common share of Ventripoint and one common share warrant. Each warrant will entitle the holder thereof to acquire one common share at a price of 50 cents per common share for a period of two years after the issuance of the warrant.

The corporation is also announcing the private placement is oversubscribed and no further orders will be accepted. The corporation expects to close the private placement on or before March 21, 2017.

The corporation also announces that it has expressions of interest to enter into agreements with holders of debentures previously issued by the corporation to issue an additional 1,915,625 units to the holders of the debentures as payment in full of $613,000, being the aggregate of all amounts due under the debentures, as a share-for-debt transaction. Should all debenture holders complete the transactions, the corporation would be debt free. One insider of the corporation, Dr. George Adams, would be issued 312,500 units for his $100,000 debenture.

VentriPoint shares were up 18% at C$0.46 on Wednesday.



Register here to be notified of future VPT Company articles
View full VPT profile

VentriPoint Diagnostics Timeline

Newswire
March 10 2017

Related Articles

picture of pregnant woman
February 07 2017
MyLotus has been developed for women who have been trying to conceive for six months or more.
Microbes
April 16 2017
Stephen O’Hara created Opti as a company all by himself in 2012 as a business focused on the rapidly growing microbiome space, which harnesses the positive benefits of microbes that live on the human body
Genetic data
July 12 2016
Drug discovery company snaps up software system for "non-material" sum
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use